LVEF

Revolutionizing Oncology Care: AI-Powered Ultrasound Device Enhances Cardiac Monitoring for Chemotherapy Patients

Retrieved on: 
Donnerstag, Mai 30, 2024
Nursing, Algorithm, Patient, Cancer, LVEF, Organization, European Heart Journal, Echocardiography, Cardiology, Health, Medical imaging

REDMOND, Wash., May 30, 2024 (GLOBE NEWSWIRE) -- A recent study published in the European Heart Journal highlights the significant enhancements that the Kosmos ultrasound system, developed by EchoNous, brings to cardiac evaluations for chemotherapy patients.

Key Points: 
  • REDMOND, Wash., May 30, 2024 (GLOBE NEWSWIRE) -- A recent study published in the European Heart Journal highlights the significant enhancements that the Kosmos ultrasound system, developed by EchoNous, brings to cardiac evaluations for chemotherapy patients.
  • This AI-powered device enables even non-expert ultrasound users, such as junior oncologists and nurses, to accurately and swiftly assess left ventricular ejection fraction (LVEF), a crucial indicator of heart health and a critical measure to monitor in patients undergoing chemotherapy treatment.
  • Dr. Dimitri Dionysopolous, one of the study's authors, highlighted the Komsos’s significant impact: “With very little training, oncology staff can accurately measure a patient's heart function in real-time.
  • These promising results suggest a future where Kosmos could be widely used by oncology staff, leading to faster clinical workflows and enhanced care for cancer patients.

Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy

Retrieved on: 
Donnerstag, Mai 23, 2024
Risk, Obesity, ESS, ResMed, Ageing, SAN, ATS, Woman, ASV, Therapy, University of California, ASX, Plan, Health care, LVEF, Coronary artery disease, Sleep, Grenoble Alpes University, Literature review, Natural language processing, Conference, CSA, Circulatory system, Meta-analysis, BMI, AHI, Clinical trial, NIV, Obstructive sleep apnea, Qualitative Research (journal), Comorbidity, Depression, NYHA, Sleep disorder, Hospital, Research, OSA, COPD, Central sleep apnea, PAP, Patient, Education, Qualitative, RMD, Prevalence, University, Overalls, Mortality, Death, Abstract, Economy, Adaptation, Quality of life, Pharmaceutical industry

SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- A number of accomplished medical and scientific experts presented critical new research on sleep conditions and their effect on cardiovascular health at the American Thoracic Society International Conference. The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits. The studies were among 26 supported by ResMed (NYSE: RMD, ASX: RMD) in collaboration with leading scientists including Michael Arzt, MD, Universitätsklinikum Regensburg, Germany; Jean-Louis Pépin, MD, Grenoble Alpes University, France; Atul Malhotra, MD, University of California, San Diego; and Holger Woehrle, Ulm Lung Centre, Germany.

Key Points: 
  • The ResMed-supported research provided new insights into the effectiveness of PAP therapy in treating sleep-disordered breathing and its associated clinical benefits.
  • Several studies demonstrated findings showing continued effectiveness of PAP therapies for patients with sleep disorder conditions like obstructive sleep apnea.
  • This finding demonstrates a correlation between the use of PAP therapy and a reduction in use of healthcare resources.
  • Two studies evaluated the effects of Adaptive Servo-Ventilation (ASV) therapy in two populations, patients with TE-CSA and patients on long-term opioid therapy.

Study Design and Baseline Characteristics of Prespecified, Exploratory Pooled Analysis to Investigate Effect of Finerenone on Cardio-Kidney Outcomes in Patients with CKD and Type 2 Diabetes and/or Heart Failure Shared at Heart Failure 2024 Congress

Retrieved on: 
Montag, Mai 13, 2024
Research, Diabetes, Clinical Trials, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, Science, Type 2 diabetes, Patient, LVEF, HF, Finerenone, Heart failure, ESC, FACP, Chronic kidney disease, CKM, CKD, Albuminuria, Natriuresis, Bayer, EGFR, Glomerular filtration rate, History, Pharmaceutical industry

The study design and baseline characteristics of FINE-HEART, a new prespecified, exploratory pooled analysis of three Phase III trials with finerenone1, were presented today as a Late-Breaking Science Session at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC) in Lisbon.

Key Points: 
  • The study design and baseline characteristics of FINE-HEART, a new prespecified, exploratory pooled analysis of three Phase III trials with finerenone1, were presented today as a Late-Breaking Science Session at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC) in Lisbon.
  • Finerenone is marketed as Kerendia® and approved for the treatment of adults with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in more than 70 countries worldwide, including the United States.
  • The data presented here may discuss a use outside of the approved indication.
  • FINE-HEART is designed to investigate the effects of finerenone on cardio-kidney outcomes based on data from over 19,000 patients with varying combinations of heart failure (HF), CKD and T2D across three Phase III finerenone studies – FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF.1
    Over 92% of patients included in the analysis had overlapping cardio-kidney-metabolic (CKM) conditions—78% had two (HF and CKD, HF and T2D or CKD and T2D), while 14.7% had all three.

Bayer to Present Investigational Data from Comprehensive KERENDIA® (finerenone) Clinical Trial Program at Heart Failure 2024 Congress

Retrieved on: 
Freitag, Mai 10, 2024
Health, Other Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Type 2 diabetes, Patient, LVEF, HF, Finerenone, Clinical trial, T2D, Heart failure, Safety, ESC, Chronic kidney disease, CKM, Congress, CKD, Abstract, Pharmaceutical industry

Bayer will present Kerendia® (finerenone) data from its comprehensive clinical trial program in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in addition to data from FINEARTS-HF, the ongoing randomized, double-blind, placebo-controlled, multicenter, event-driven Phase III study is investigating the efficacy (including CV death and total HF events) and safety of finerenone compared to placebo in patients suffering from symptomatic HF with an ejection fraction of ≥40% (HFmrEF/HFpEF), at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC), taking place May 11-14, 2024 in Lisbon, Portugal.

Key Points: 
  • Bayer will present Kerendia® (finerenone) data from its comprehensive clinical trial program in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) in addition to data from FINEARTS-HF, the ongoing randomized, double-blind, placebo-controlled, multicenter, event-driven Phase III study is investigating the efficacy (including CV death and total HF events) and safety of finerenone compared to placebo in patients suffering from symptomatic HF with an ejection fraction of ≥40% (HFmrEF/HFpEF), at Heart Failure 2024, a scientific congress of the European Society of Cardiology (ESC), taking place May 11-14, 2024 in Lisbon, Portugal.
  • Finerenone is marketed as Kerendia® and approved for the treatment of adults with CKD associated with T2D in more than 70 countries worldwide, including the United States.
  • The abstracts may discuss a use outside of the approved indication.
  • Data will include a new pre-specified pooled analysis of three Phase III trials, FINE-HEART, with finerenone, insights around the overlapping nature of cardio-kidney-metabolic (CKM) conditions, additional risks associated with HF with LVEF ≥40%, and the use of gamification to enhance clinical trial recruitment.

Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Retrieved on: 
Mittwoch, Mai 8, 2024
DSM-IV codes, Patient, Adolescence, Safety, Obstruction, LVEF, Risk, Pharmacokinetics, Cytokinetics, NYHA, Research and development, Arrhythmia, Mercury (element), Library classification, Heart failure, Clinical trial, Quality of life, SAN, Ageing

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM (Clinical Evaluation of Dosing with Aficamten to Reduce Obstruction in a Pediatric Population in HCM), a clinical trial of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM (Clinical Evaluation of Dosing with Aficamten to Reduce Obstruction in a Pediatric Population in HCM), a clinical trial of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment.
  • Aficamten is a next-in-class cardiac myosin inhibitor in development for the potential treatment of HCM.
  • HCM can present similarly in adolescents and children as it does in adults and may negatively impact overall quality of life.
  • Patients will be randomized on a 2:1 basis to receive aficamten or placebo, and those receiving aficamten will begin with 5 mg dosed once daily.

Exo® Launches FDA-Cleared AI on Exo Iris™ to Address Heart Failure

Retrieved on: 
Dienstag, April 23, 2024
Technology, Medical Devices, FDA, Health Technology, Cardiology, Software, Other Health, Health, Artificial Intelligence, Stroke, Ecosystem, LVEF, Hip, Pulmonary edema, Heart, Echocardiography, Patient, Physician, POCUS, Caregiver, Northwestern Medicine, CHF, Lung, Iris, Multimedia, Diagnosis, Heart failure, Emergency medicine, COPD, Medical device

The number of Americans with heart failure today is over 6.7 million and growing.

Key Points: 
  • The number of Americans with heart failure today is over 6.7 million and growing.
  • While echocardiography is the cornerstone of heart failure diagnosis, it is costly and requires highly trained sonographers to use it.
  • Exo’s revolutionary ecosystem includes Exo Iris, as well as a fast-growing suite of AI solutions and its award-winning POCUS workflow software, Exo Works® .
  • To purchase Exo Iris and the rest of Exo’s medical imaging ecosystem, visit Exo’s website or contact us to learn more.

GE HealthCare Introduces Caption AI on Vscan Air SL Wireless Handheld Ultrasound System to Help More Clinicians Capture Diagnostic-Quality Cardiac Images

Retrieved on: 
Mittwoch, April 3, 2024
Technology, Mobile, Wireless, Health, Apps, Applications, Radiology, Professional Services, Artificial Intelligence, Medical Devices, Software, Hospitals, Data Analytics, Health Technology, Data Management, Cardiology, Diagnosis, Cardiovascular disease, Prevalence, CVD, Intelligence, Patient, Acquisition, Death, Master of Science, LVEF, Caption, American College, GE HealthCare, Heart, Atrial fibrillation, ACC, Medical imaging

GE HealthCare (Nasdaq: GEHC) today announced the launch of Caption AI artificial intelligence (AI)-driven software for rapid cardiac assessments at the point of care on Vscan Air SL.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC) today announced the launch of Caption AI artificial intelligence (AI)-driven software for rapid cardiac assessments at the point of care on Vscan Air SL.
  • Now, with Caption AI technology, clinicians using Vscan Air SL handheld ultrasound will have access to real-time, step-by-step guidance to capture diagnostic-quality images and automated ejection fraction estimation to help inform clinical decisions across cardiac settings.
  • Vscan Air SL with Caption AI is designed to lower the threshold for healthcare professionals to be able to capture cardiac images so that even non-expert ultrasound users can take a quick look at patients’ hearts.
  • "The integration of Caption AI with the Vscan Air SL handheld ultrasound opens an entirely new chapter for cardiac screening.

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio

Retrieved on: 
Montag, März 25, 2024
Health, Clinical Trials, General Health, Pharmaceutical, Cardiology, Biotechnology, BMY, Patient, Mitigation, Bristol Myers Squibb, MD, Senior, LVEF, American College, Safety, REMS, ACC, Risk, Hospital, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American College of Cardiology (ACC) Annual Scientific Session & Expo, taking place April 6-8, 2024 in Atlanta, Georgia.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American College of Cardiology (ACC) Annual Scientific Session & Expo, taking place April 6-8, 2024 in Atlanta, Georgia.
  • These data are consistent with the clinical development program and reinforce the safety profile of CAMZYOS in clinical practice.
  • This effectiveness and safety information about ELIQUIS use in clinical practice can supplement data from randomized clinical trials.
  • Visit this page on BMS.com for more information on Bristol Myers Squibb’s scientific approach and resources on cardiovascular diseases.

Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Retrieved on: 
Mittwoch, März 6, 2024
MRI, Therapy, SAN, Biotechnology, Skeleton, FDA, DMD, Duchenne muscular dystrophy, Conference, Patient, OLE, Cardiac muscle, Exosome, MDA, LVEF, Episcopal conference, PUL, Pharmaceutical industry

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD) at this year’s MDA Clinical and Scientific Conference which is taking place in Orlando, Florida from March 3-6, 2024.

Key Points: 
  • SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD) at this year’s MDA Clinical and Scientific Conference which is taking place in Orlando, Florida from March 3-6, 2024.
  • CAP-1002 revealed clinically meaningful improvements in ameliorating cardiac function.
  • “We are pleased to be presenting our positive long-term open label extension data at this year’s MDA Conference,” said Linda Marbán, Ph.D., chief executive officer of Capricor.
  • These two-year results suggest that CAP-1002 has the potential to slow the decline of DMD progression and speaks to the potential long-term benefit for patients.

Veradigm Reveals New Insights on the Prevalence of Cardiovascular Conditions in the U.S.

Retrieved on: 
Dienstag, Februar 20, 2024
Data Management, Health, Technology, Health Technology, Software, General Health, Cardiology, Real-World Evidence, Woman, Cardiovascular disease, EHR, CVD, MDRX, Data, Heart failure, Prevalence, Natural language processing, Hypertension, BMI, Death, Patient, Natural language, Body mass index, LVEF, Coronary artery disease, NLP, Dietary supplement

Veradigm today released its inaugural Veradigm Insights Report: Cardiovascular Conditions in 2024, which examines de-identified real world data for 53 million unique cardiovascular patients.

Key Points: 
  • Veradigm today released its inaugural Veradigm Insights Report: Cardiovascular Conditions in 2024, which examines de-identified real world data for 53 million unique cardiovascular patients.
  • Using structured and unstructured data from the comprehensive Veradigm Network EHR dataset, the report presents cardiovascular condition prevalence by state and three-digit zip code.
  • Veradigm also examines the prevalence of cardiovascular conditions such as dyslipidemia/hyperlipidemia and hypertension in relation to body mass index (BMI) categories.
  • Veradigm has a variety of additional data sources including clinically enriched Veradigm Network EHR Data across various therapeutic areas and the Veradigm Cardiovascular and Metabolic Registries.